Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Changes to medical policies regarding Stem-Cell Therapy

May 9, 2022

​For dates of service on or after July 11, 2022, Independence will update its medical policies on Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions for Commercial and Medicare Advantage members.

Autologous platelet-rich plasma (PRP) for the treatment of all orthopedic conditions is considered experimental/investigational effective July 11, 2022, for both Commercial and Medicare Advantage members.

For detailed changes, please refer to the Commercial and Medicare Advantage Policy Notifications, which were posted on April 11, 2022.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.